Dr Peter Dull | Deputy Director, Integrated Clinical Vaccine Development
The Bill & Melinda Gates Foundation

Dr Peter Dull, Deputy Director, Integrated Clinical Vaccine Development, The Bill & Melinda Gates Foundation

Peter Dull, MD, MS, is Deputy Director for Integrated Clinical Vaccine Development within the Global Health Division at The Bill & Melinda Gates Foundation. In this role he provides technical and strategic guidance to the foundation's program strategy teams and external partners. During the Ebola response, he was seconded to WHO to support in facilitating clinical trial coordination in West Africa. He joined the foundation after 10 years at Novartis Vaccines and Diagnostics, where he was the Clinical Franchise Head for Meningitis and Sepsis Vaccines. At Novartis, he led the clinical development and global licensure for infants, adolescents, and adults of a quadrivalent meningococcal glycoconjugate vaccine (Menveo®; MenACWY-CRM) as well as a protein-based serogroup B vaccine (Bexsero®; 4CMenB). In addition, he led the clinical development for the Group B strep glycoconjugate vaccine, which is targeted to pregnant women to prevent neonatal disease. Prior to joining Novartis, he was an Epidemic Intelligence Service officer in the Meningitis and Special Pathogens Branch at the U.S. Centers for Disease Control and Prevention (CDC), where he was responsible for conducting ongoing surveillance and investigating outbreaks of pathogens such as meningococcus and Bacillus anthracis. Dr. Dull holds a BS in physics and an MS in neuroscience. He attended medical school at the University of Wisconsin–Madison and completed his internal medicine training at Oregon Health & Science University in Portland, Oregon. After his service as an Epidemic Intelligence Officer, he completed subspecialty training in infectious diseases at Emory University.


DC Co-conference Day 2 April 4 @ 5:10

A double perspective from both sides: How to foster vaccine partnerships

  • Lesson learned in global access agreements
  • Catalytic funding
Partner to be announced

back to speakers